Explore the words cloud of the PHA-ST-TRAIN-VAC project. It provides you a very rough idea of what is the project "PHA-ST-TRAIN-VAC" about.
The following table provides information about the project.
UNIVERSITY OF STRATHCLYDE
|Coordinator Country||United Kingdom [UK]|
|Total cost||1˙062˙698 €|
|EC max contribution||1˙062˙698 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2016-06-01 to 2020-05-31|
Take a look of project's partnership.
|1||UNIVERSITY OF STRATHCLYDE||UK (GLASGOW)||coordinator||546˙575.00|
|2||GLAXOSMITHKLINE VACCINES SRL||IT (SIENA)||participant||516˙122.00|
Immunisation is one of the most cost-effective and proven tools to control and eliminate infectious diseases, saving millions of lives each year, yet key challenges remain in order to guarantee the future health of the expanding and ageing global population. For example, effective vaccines are still required for Respiratory Syncytial Virus (RSV) and Group B Streptococcus (GBS), both of which cause significant hospitalisations globally each year. RSV is a common cause of respiratory disease among all age groups; annually it results in an estimated 33.8 million acute lower respiratory tract infections (resulting in 66,000-199,000 deaths) and among the elderly, it results in as many hospitalisations as influenza. Group B Streptococcus (GBS) infections also pose a serious risk; GBS is a leading cause of invasive infections in pregnant women, new-born infants, and the elderly. To meet the challenge of developing fit-for-purpose, age-appropriate vaccines against these disease targets, this EID will bring together two cross-sector, world leading teams – GSK Vaccines S.r.L and the University of Strathclyde – with the objective to equip the next generation of vaccinologists with the skills and tools to deliver vaccines for the 21st Century. GSK Vaccines S.r.L is a global leader in vaccine research, development and production and will work in partnership with the vaccine team within USTRATH and the Strathclyde Institute of Pharmacy and Biomedical Sciences, who have an international track-record of translatable and innovative research in immunology, immunomodulation, structural biology, and formulation design and pharmaceutical engineering of vaccine systems. PHA-ST-TRAIN-VAC will deliver a unique, multidisciplinary and intersectoral training programme to develop and equip four early stage researchers with the required skills and entrepreneurship to develop new vaccines to protect against RSV and GBS, in a formulation tailored to the age of the patient.
|Identification of RSV antigen for alternative vaccination routes||Documents, reports||2020-04-08 10:20:48|
|Bio-distribution of adjuvants and their associated antigen - 1||Documents, reports||2020-04-08 10:20:48|
|Data management plan||Open Research Data Pilot||2020-04-08 10:20:48|
|Interactions of GBS and RSV antigen and adjuvants||Documents, reports||2020-04-08 10:20:48|
|Key biophysical and physico-chemical attributes of current lipid nanoparticles||Documents, reports||2020-04-08 10:20:48|
|Metabolic factors that contribute to the impaired adaptive immunity in older adults||Documents, reports||2020-04-08 10:20:48|
|Bio-distribution of lipid nanoparticles||Documents, reports||2020-04-08 10:20:47|
|Key physico-chemical attributes of alum, emulsion, liposome and nanoparticle systems shown to be effective as adjuvants||Documents, reports||2020-04-08 10:20:47|
|Model to investigate intracellular ROS, antigen presentation and specific T cell responses||Documents, reports||2020-04-08 10:20:48|
|Identification of self-amplifying RSV RNA construct||Documents, reports||2020-04-08 10:20:48|
|Comparison of cellular uptake in monocyte-derived macrophages and dendritic cells||Documents, reports||2020-04-08 10:20:48|
Take a look to the deliverables list in detail: detailed list of PHA-ST-TRAIN-VAC deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHA-ST-TRAIN-VAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PHA-ST-TRAIN-VAC" are provided by the European Opendata Portal: CORDIS opendata.
Targeted Anti-Cancer TherapiesRead More
Exploitation of the SECRETory pathway for cancer therapy to address European researchRead More
A training network for the design of new synthetic carbohydrate-based vaccines to combat antibiotic resistant Pseudomonas aeruginosaRead More